￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

Can all cancers with NTRK gene fusions be treated with larotrectinib?

2025-10-19 11:44:20

Check Details
Larotrectinib is the first oral pan-cancer targeted drug that can be used by children and adults with NTRK gene fusions in different tumors_ Kanghule

2025-10-19 11:44:20

Check Details
The second-generation ALK inhibitor, aletinib, is approved by the FDA as a first-line drug for ALK treatment

2025-10-19 11:44:20

Check Details
ALK/ROS1 inhibitor lorlatinib was granted breakthrough drug designation by the FDA_ Kanghule

2025-10-19 11:44:20

Check Details
Larotrectinib has significant effects in the treatment of NTRK mutation-positive lung cancer

2025-10-19 11:44:20

Check Details
The efficacy and tolerability of alectinib in the treatment of ALK-positive advanced non-small cell lung cancer are better than chemotherapy_ Kanghule

2025-10-19 11:44:20

Check Details
Safety and effectiveness of alectinib in the treatment of ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
NTRK-targeting drug larotinib brings hope to patients

2025-10-19 11:44:20

Check Details
Has the third-generation ALK inhibitor lorlatinib been approved for marketing in China?

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking larotinib

2025-10-19 11:44:20

Check Details
How much will the out-of-pocket cost of aletinib be after medical insurance reimbursement in 2021?

2025-10-19 11:44:20

Check Details
ALK inhibitor lorlatinib in the treatment of non-small cell lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
Category
相关知识